$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018]

Published by Delve Insight: 14 Feb 2018 | 201242 | In Stock

Introduction

Introduction

DelveInsight's, “Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report provides comprehensive insights about marketed and Phase III products for Metastatic Renal Cell Carcinoma (mRCC) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Metastatic Renal Cell Carcinoma (mRCC)

Coverage of API manufacturers for Metastatic Renal Cell Carcinoma (mRCC) marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.

Emerging Phase III products for Metastatic Renal Cell Carcinoma (mRCC)

This report provides a comprehensive understanding of the emerging Phase III therapies for Metastatic Renal Cell Carcinoma (mRCC) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Methodology

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.

Scope

• A review of the marketed products for Metastatic Renal Cell Carcinoma (mRCC) including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details.

• Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details

• API manufacturers for the marketed products with location details

• Emerging Phase III product profiles for Metastatic Renal Cell Carcinoma (mRCC) including product description, developmental activities, licensors & collaborators and chemical information

Reasons to Buy

• API intelligence for marketed drugs for the indication and gaining insights of API manufacturers

• Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication

• Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space

Table of Contents
for Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018]

  • 1. Report Introduction

    2. Metastatic Renal Cell Carcinoma (mRCC) : Overview

    • Risk Factors

    • Causes

    • Symptoms

    • Pathophysiology

    • Prognosis

    • Diagnosis

    • Treatment

    3. Comparative Analysis of Marketed and Emerging Products

    4. Marketed Therapies

    4.1. Drug 1: Company name

    • Product Description

    • Route of Synthesis

    • Mechanism of Action

    • Pharmacology

    • Pharmacodynamics

    • Pharmacokinetics

    • Adverse Reactions

    • Clinical Trials

    • Regulatory Milestones

    • Product Development Activities

    4.1.1 Product Details

    • United States

    • Europe

    4.1.2 Global Sales Assessment

    • Historical Global Sales

    • Forecasted Global Sales

    4.1.3 Patent Details

    Other marketed products in the detailed report…

    5. Emerging Therapies (Phase III)

    5.1 Drug Name : Company Name

    • Product Description

    • Research and Development

    • Product Development Activities

    5.1.1 Forecasted Global Sales

    Other Phase III profiles in the detailed report…

    Appendix

    Methodology

    Consulting Services

    About DelveInsight

    Contact Us

List Of Tables
in Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018]

Table 1: List of Marketed and Emerging Products

Table 2: Drug Product Details, United States

Table 3: Drug Product Details, Europe

Table 4: Drug, Historical Global Sales till 2017 (in million USD)

Table 5: Drug, Forecasted Global Sales from 2018-2020 (in million USD)

Table 6: API Manufacturers Region wise

Table 7: API Manufacturers for United States

Table 8: API Manufacturers for Europe

Table 9: API Manufacturers for China

Table 10: API Manufacturers for India

Table 11: Patent Details

Table 12: Emerging Therapies (Phase III)

Table 13: Drug, Forecasted Global Sales from 2018-2020 (in million USD)

List Of Figures, Charts and Diagrams
in Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018]

Figure 1: Comparative Analysis of Marketed and Emerging Products

Figure 2: Drug, Historical Global Sales till 2017 (in million USD)

Figure 3: Drug, Forecasted Global Sales from 2018-2020 (in million USD)

Figure 4: Patent Details

Figure 5: API Manufacturers Region wise

Figure 6: Drug, Forecasted Global Sales from 2018-2020 (in million USD)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

201242 | DIIT0070

Number of Pages

60

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data